Aditxt Inc is a biotech company focused on enhancing the immune system through innovative technologies designed to promote immune tolerance
The company seeks to develop therapies that can help manage and treat immune-related diseases by leveraging its proprietary platform to create customized solutions. Aditxt's research and development efforts aim to address a range of immunological disorders, potentially transforming the landscape of immunotherapy and improving patient outcomes through better immune system management.
Aditxt's wholly owned subsidiary, Adivir, Inc. will acquire all issued and outstanding Class A common shares of Appili in the transaction. Appili has developed FDA-approved Likmez (previously ATI-1501), its ATI-1701 biodefense program supported by a USD $14 million non-dilutive award from the U.S Department of Defense, and its ATI-1801 topical formulation targeting cutaneous leishmaniasis.
